Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.00 USD
Change Today -0.01 / -0.50%
Volume 31.1K
BIOL On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

biolase inc (BIOL) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/5/14 - $3.00
52 Week Low
05/14/14 - $1.69
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOLASE INC (BIOL)

Related News

No related news articles were found.

biolase inc (BIOL) Related Businessweek News

No Related Businessweek News Found

biolase inc (BIOL) Details

BIOLASE, Inc., a medical device company, develops, manufactures, and markets laser systems in dentistry and medicine in the Unites States and internationally. It offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used in soft tissue, pain therapy, and cosmetic procedures, such as teeth whitening. The company’s dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, including cosmetic, restorative, and complex surgical applications. It also markets and distributes dental imaging equipment, including cone beam digital X-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional (3-D) printers, as well as provides precision intuitive diagnosis and treatment planning solutions. The company’s dental imaging products comprise 3Shape Trios CAD/CAM digital impression systems, which are spray-free scanning devices; Galaxy BioMill CAD/CAM system that enables dental practitioners to complete scanning, designing, milling, and finishing of crowns, inlays, and veneers in the dental office; and 3-D printers that allow dentists to fabricate stone models, orthodontic appliances, delivery and positioning trays, models for clear aligners, retainers, and surgical guides on their desktop. In addition, it manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. The company sells its products primarily to dentists in general practice through its direct sales force and distributor network. BIOLASE, Inc. has a strategic agreement with Valam, Inc. to develop, market, and sell office-based laser systems to otolaryngologists. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

210 Employees
Last Reported Date: 03/6/15
Founded in 1984

biolase inc (BIOL) Top Compensated Officers

Vice President of Research and Development
Total Annual Compensation: $250.0K
Director of Professional Relations
Total Annual Compensation: $90.0K
Compensation as of Fiscal Year 2013.

biolase inc (BIOL) Key Developments

BIOLASE, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

BIOLASE, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company's net revenue was $13,238,000 compared to $15,241,000 a year ago. Loss from operations was $3,819,000 compared to $2,026,000 a year ago. Loss before income tax benefit was $4,074,000 compared to $2,216,000 a year ago. Net loss was $4,104,000 compared to $2,234,000 a year ago. Basic and diluted net loss per share was $0.08 compared to $0.06 a year ago. Non-GAAP net loss was $3,555,000 compared to $1,365,000 a year ago. Non-GAAP net loss per share, basic and diluted was $0.06 compared to $0.05 a year ago. For the year, the company's net revenue was $47,656,000 compared to $56,430,000 a year ago. Loss from operations was $17,941,000 compared to $10,996,000 a year ago. Loss before income tax benefit was $18,814,000 compared to $11,646,000 a year ago. Net loss was $18,926,000 compared to $11,482,000 a year ago. Diluted net loss per share was $0.45 compared to $0.35 a year ago. Non-GAAP net loss was $16,304,000 compared to $8,480,000 a year ago. Non-GAAP net loss per share, basic and diluted was $0.38 compared to $0.26 a year ago.

BIOLASE Names David C. Dreyer Chief Financial Officer to Replace Frederick D. Furry

BIOLASE, Inc. announced that it has hired veteran financial executive David C. Dreyer as its Chief Financial Officer. He will report to BIOLASE President and CEO Jeffrey M. Nugent and join the company, effective March 9. Mr. Dreyer replaces Frederick D. Furry, who resigned January 31 to pursue other opportunities. Most recently, from 2010 to 2014, Mr. Dreyer was Chief Financial Officer of Irvine, CA-based Patient Safety Technologies Inc.

BIOLASE, Inc. Announces the Launch of the New WaterLase IPlus 2.0

BIOLASE, Inc. introduced dentistry’s first-ever Practice Growth Guarantee with the launch of the new, advanced WaterLase iPlus 2.0. WaterLase iPlus 2.0, the next generation of the world’s most-preferred all-tissue laser, will debut this week in the BIOLASE booth (#601) at the Chicago Dental Society’s Mid-Winter Meeting at McCormick Place West. The new laser includes important innovations and improvements resulting in satisfied patients and dental practice growth. WaterLase iPlus 2.0 also marks the debut of the SureFire YSGG Delivery System which ensures greater uptime and routine use for dentists. In addition, the laser integrates REPaiR as an app for minimally invasive treatment of periodontitis. The unique Practice Growth Guarantee is an assurance that WaterLase iPlus 2.0 will make a difference by enhancing the patient experience and generating practice growth through routine use. The WaterLase iPlus 2.0 offers key refinements and updates, including: Upgraded components to improve overall quality and performance during daily, routine use. Optimized procedure pre-sets to help dentists achieve clinical success more consistently. Improved “i” button on the main screen for easier access to help screens. The SureFire YSGG Delivery System, which results in more dependability and uptime for the dentist, includes: Redesigned optics that can more efficiently deliver precise amounts of laser energy to cut enamel, dentin and bone, in addition to the soft tissue capabilities for which the WaterLase franchise is known. A replaceable, disposable shield that protects the vital optical components in the SureFire fiber. The REPaiR laser perio app: Was based on years of clinical development by a team of periodontists and dentists from around the world including noted periodontist, educator and innovator. Includes clinical illustrations and pre-programmed settings for each step of the protocol to ensure consistent results.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOL:US $2.00 USD -0.01

BIOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $4.14 USD +0.09
Cutera Inc $13.23 USD -0.07
Cytori Therapeutics Inc $1.19 USD +0.01
Stereotaxis Inc $2.08 USD +0.01
Uroplasty Inc $1.30 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLASE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at